Usefulness of albumin-globulin ratio as a clinical prognostic factor in patients with thyroid cancer treated with radioiodine.
Albumin–globulin ratio
Overall survival
Radioactive iodine
Thyroid cancer
Journal
Annals of nuclear medicine
ISSN: 1864-6433
Titre abrégé: Ann Nucl Med
Pays: Japan
ID NLM: 8913398
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
04
03
2021
accepted:
20
05
2021
pubmed:
2
6
2021
medline:
31
12
2021
entrez:
1
6
2021
Statut:
ppublish
Résumé
Albumin-globulin ratio (AGR), which is calculated by dividing serum albumin by serum globulin, is considered as a cancer-related inflammation biomarker. Although the prognosis of many solid cancers has been shown to be associated with AGR, there are no studies to demonstrate the association between the prognosis of thyroid cancer and AGR. The purpose of this study is to reveal the relationship between AGR and overall survival (OS) in patients with thyroid cancer who received radioactive iodine therapy (RIT). Eighty-eight patients with thyroid cancer who had received RIT for the first time in our institution were included. The values before RIT were adopted as initial measurements for serum albumin, globulin, and thyroglobulin (Tg) and used for analysis. Patients were divided into two groups based on the AGR value. We analyzed the relationship between clinical factors and treatment outcome. The median follow-up period was 92.4 months (range: 30.1-173.9 months). The 5-year OS and progression-free survival (PFS) were 94% and 54%, respectively. Seventeen patients (< 65 years, 8; and ≥ 65 years, 9) died during the follow-up period. Low AGR was significantly associated with OS in both univariate and multivariate analyses (p = 0.0059 and p = 0.0120, respectively). As the 5-year OS was as high as 94%, there was no significant difference in survival rate between the two groups during the first 5 years. However, there seemed to be a remarkable difference in 10 years after the first RIT. On the other hand, Tg was significantly associated with PFS in both univariate and multivariate analyses (p = 0.0016 and p = 0.0441, respectively). In patients under the age of 65, the PFS rate was significantly lower in the low AGR group (p < 0.0001), while there was no difference in PFS rate between the two AGR groups in patients aged 65 years or older. AGR may be used as a prognostic factor in relatively younger patients with thyroid cancer treated with radioiodine, while it may be less useful in the older. Overall, it may be an independent prognostic factor for long-term survival in those with thyroid cancer.
Identifiants
pubmed: 34061291
doi: 10.1007/s12149-021-01635-2
pii: 10.1007/s12149-021-01635-2
doi:
Substances chimiques
Iodine Radioisotopes
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1015-1021Informations de copyright
© 2021. The Japanese Society of Nuclear Medicine.
Références
Vecchia CL, Malvezzi M, Bosetti C, Garavello W, Bertuccio P, Levi F, et al. Thyroid cancer mortality and incidence: a global overview. Int J Cancer. 2015;136:2187–95.
doi: 10.1002/ijc.29251
Song H-J, Qiu Z-L, Shen C-T, Wei W-J, Luo Q-Y. Pulmonary metastases in differentiated thyroid cancer: efficacy of radioiodine therapy and prognostic factors. Eur J Endocrinol. 2015;173:399–408.
doi: 10.1530/EJE-15-0296
Nixon IJ, Whitcher MM, Palmer FL, Tuttle RM, Shaha AR, Shah JP, et al. The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland. Thyroid. 2012;22:884–9.
doi: 10.1089/thy.2011.0535
Wang R, Zhang Y, Tan J, Zhang G, Zhang R, Zheng W, et al. Analysis of radioiodine therapy and prognostic factors of differentiated thyroid cancer patients with pulmonary metastasis: an 8-year retrospective study. Medicine (Baltimore). 2017. https://doi.org/10.1097/MD.0000000000006809 .
doi: 10.1097/MD.0000000000006809
pubmed: 29137095
pmcid: 5945951
Bandeira L, Padovani RDP, Ticly AL, Cury AN, Scalissi NM, Marone MMS, et al. Thyroglobulin levels before radioactive iodine therapy and dynamic risk stratification after 1 year in patients with differentiated thyroid cancer. Arch Endocrinol Metab. 2017;61:590–9.
doi: 10.1590/2359-3997000000308
Choi YM, Kim WG, Kwon H, Jeon MJ, Lee JJ, Ryu J-S, et al. Early prognostic factors at the time of diagnosis of bone metastasis in patients with bone metastases of differentiated thyroid carcinoma. Eur J Endocrinol. 2016;175:165–72.
doi: 10.1530/EJE-16-0237
Spencer CA, Takeuchi M, Kazarosyan M, Wang CC, Guttler RB, Singer PA, et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 1998;83:1121–7.
pubmed: 9543128
Görges R, Maniecki M, Jentzen W, Sheu SN-Y, Mann K, Bockisch A, et al. Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy. Eur J Endocrinol. 2005;153:49–55.
doi: 10.1530/eje.1.01940
He J, Pan H, Liang W, Xiao D, Chen X, Guo M, et al. Prognostic effect of albumin-to-globulin ratio in patients with solid tumors: a systematic review and meta-analysis. J Cancer. 2017;8:4002–10.
doi: 10.7150/jca.21141
Königsbrügge O, Posch F, Riedl J, Reitter E-M, Zielinski C, Pabinger I, et al. Association between decreased serum albumin with risk of venous thromboembolism and mortality in cancer patients. Oncologist. 2016;21:252–7.
doi: 10.1634/theoncologist.2015-0284
Shimizu T, Ishizuka M, Shibuya N, Tanaka G, Abe A, Aoki T, et al. Preoperative globulin-to-albumin ratio predicts outcome after curative resection in patients with gastric cancer. Ann Gastroenterol Surg. 2018;2:367–75.
doi: 10.1002/ags3.12200
Hachiya H, Ishizuka M, Takagi K, Iwasaki Y, Shibuya N, Nishi Y, et al. Clinical significance of the globulin-to-albumin ratio for prediction of postoperative survival in patients with colorectal cancer. Ann Gastroenterol Surg. 2018;2:434–41.
doi: 10.1002/ags3.12201
Xu Y, Xu X, Xi C, Ye N, Wang Y. Prognostic value of preoperative albumin to globulin ratio in elderly patients with rectal cancer. Medicine (Baltimore). 2019. https://doi.org/10.1097/MD0000000000016066 .
doi: 10.1097/MD0000000000016066
pubmed: 31676459
pmcid: 7720680
Duran AO, Inanc M, Karaca H, Dogan I, Berk V, Bozkurt O, et al. Albumin-globulin ratio for prediction of long-term mortality in lung adenocarcinoma patients. Asian Pac J Cancer Prev. 2014;15:6449–53.
doi: 10.7314/APJCP.2014.15.15.6449
Deng Y, Pang Q, Miao R-C, Chen W, Zhou Y-Y, Bi J-B, et al. Prognostic significance of pretreatment albumin/globulin ratio in patients with hepatocellular carcinoma. Oncol Targets Ther. 2016;9:5317–28.
doi: 10.2147/OTT.S109736
Koparal MY, Polat F, Cetin S, Bulut EC, Sözen TS. Prognostic role of preoperative albumin to globulin ratio in predicting survival of clear cell renal cell carcinoma. Int Braz J Urol. 2018;44:933–46.
doi: 10.1590/s1677-5538.ibju.2018.0012
Hussain A, Almenfi HF, Almehdewi AM, Hamza MS, Bhat MS, Vijayashankar NP. Laboratory features of newly diagnosed multiple myeloma patients. Cureus. 2019. https://doi.org/10.7759/cureus.4716 .
doi: 10.7759/cureus.4716
pubmed: 32025387
pmcid: 6977573
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mander SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133.
doi: 10.1089/thy.2015.0020
Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in locally advanced or metastatic, radioactive iodine-refractory, differentiated thyroid cancer: a randomized, double-blind, phase 3 trial. Lancet. 2014;384:319–28.
doi: 10.1016/S0140-6736(14)60421-9
Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumors. 8th ed. Hoboken: Wiley; 2017.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.
doi: 10.1016/j.ejca.2008.10.026
Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–44.
doi: 10.1038/nature07205
Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–7.
doi: 10.1038/nature01322
Gomi I, Fukushima H, Shiraki M, Miwa Y, Ando T, Takai K, et al. Relationship between serum albumin level and aging in community-dwelling self-supported elderly population. J Nutr Sci Vitaminol. 2007;53:37–42.
doi: 10.3177/jnsv.53.37
Wu C-Y, Hu H-Y, Huang N, Chou Y-C, Li C-P, Chou Y-J. Albumin levels and cause-specific mortality in community-dwelling older adults. Prev Med. 2018;112:145–51.
doi: 10.1016/j.ypmed.2018.04.015
Salive ME, Cornoni-Huntley J, Phillips CL, Guralnik JM, Cohen HJ, Ostfeld AM, et al. Serum albumin in older persons: relationship with age and health status. J Clin Epidemiol. 1992;45:213–21.
doi: 10.1016/0895-4356(92)90081-W
Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J. 2010. https://doi.org/10.1186/1475-2891-9-69 .
doi: 10.1186/1475-2891-9-69
pubmed: 21176210
pmcid: 3019132
Zhong Z, Sanchez-Lopez KM. Autophagy, inflammation and immunity: a troika governing cancer and its treatment. Cell. 2016;166:288–98.
doi: 10.1016/j.cell.2016.05.051
Hu D, Zheng H, Liu H, Li M, Ren W, Liao W, et al. Immunoglobulin expression and its biological significance in cancer cells. Cell Mol Immunol. 2008;5:319–24.
doi: 10.1038/cmi.2008.39